AR and prostate carcinoma: Two anti-androgens, ARN-509 and MDV3100 inhibiting AR nuclear translocation and AR binding to androgen response elements [13, 14], for prostate cancer treatment have been demonstrated to significantly improve survival in men with metastatic castration-resistant prostate cancer (CRPC) in several clinical trials [15].